Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 7/20 | 0.49 |
| ▸ | F10 | P00742 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940045 | 1.00 | NPY5R (0.49) | NPY5RF10SMN1; SMN2TSHRRAB9A | |
| SCHEMBL2943739 | 0.90 | NPY5R (0.48) | NPY5RF10SMN1; SMN2TSHRRAB9A | |
| SCHEMBL2943737 | 0.90 | NPY5R (0.48) | NPY5RF10SMN1; SMN2TSHRRAB9A | |
| SCHEMBL13290759 | 0.90 | NPY5R (0.49) | NPY5RF10SMN1; SMN2TSHRLMNA | |
| SCHEMBL2947450 | 0.90 | NPY5R (0.47) | NPY5RF10SMN1; SMN2TSHRRAB9A | |
| SCHEMBL2947452 | 0.90 | NPY5R (0.47) | NPY5RF10SMN1; SMN2TSHRRAB9A | |
| SCHEMBL2949464 | 0.89 | NPY5R (0.47) | NPY5RF10SMN1; SMN2TSHRRAB9A | |
| SCHEMBL2949463 | 0.89 | NPY5R (0.47) | NPY5RF10SMN1; SMN2TSHRRAB9A | |
| SCHEMBL2947429 | 0.88 | NPY5R (0.51) | NPY5RSMN1; SMN2TSHRKDM4ETP53 | |
| SCHEMBL2947432 | 0.88 | NPY5R (0.51) | NPY5RSMN1; SMN2TSHRKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489078-B1 | BENZOFURAN DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-7531537-B2 | Benzofuran derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| CN-100439351-C | Benzofuran derivative | TANABE SEIYAKU CO (JP) | 2008-12-03 | — | — | CN | disclosed |
| US-20050282808-A1 | Benzofuran derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-22 | — | — | US | disclosed |
| CN-1656086-A | Benzofuran derivative | TANABE SEIYAKU CO (JP) | 2005-08-17 | — | — | CN | disclosed |
| EP-1489078-A1 | BENZOFURAN DERIVATIVE | Tanabe Seiyaku Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282808-A1 | Benzofuran derivative | F12, F2, F11 | NPY5R 369/4885F10 5/4885SMN1; SMN2 3151/4885 |
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | NPY5R 375/4885F10 5/4885SMN1; SMN2 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.